We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The AccelTRA® components program was developed to help generics manufacturers meet increasing quality standards, facilitate fast response to market variability and standardize around a next generation formulation for simplicity. Initially introduced with stopper configurations in 13mm and 20mm serum and lyo formats, the benefits under the program support the needs of the generics market to minimize the risk for quality by having an industry leading Extractables package, in addition to an optimized supply chain, ensuring 6-week lead times on commercial orders.
With the anticipated growth of generic drug products in Prefilled Syringe format, and to further complement the AccelTRA program, West has introduced a 1-3mL plunger. The 1-3mL plunger leverages an existing ISO plunger design that is used in many marketed drug products and has been validated to meet the requirements within the AccelTRA program. The 1-3mL AccelTRA plunger combines the QUALITY, SPEED, and SIMPLICITY provided with West’s AccelTRA components with RELIABLE performance for PFS drug applications.
Some key features of the 1-3mL AccelTRA plunger:
AccelTRA® and logo and Westar® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
For the pharmaceutical industry, the cost of developing new and innovative therapies will continue to rise (the cost of developing a drug is now estimated to be between $1.5 billion to more than $1.8 billion<sup>1</sup>).
<span style="background: white;">At West, we are by the side of our team members - supporting your training and development needs, providing opportunities to advance in your career and reach your full potential, while maintaining your well-being and work-life balance. In our Team Member Spotlight, learn more about what it is like to work at West and hear about the experiences and careers of some of our team members around the world.</span>
<span style="color: windowtext;">West</span> is pleased to announce the launch of its 10th annual West without Borders fundraising campaign!
<div class="entry-content"><p>Through the global West without Borders charitable fundraising campaign, West team members around the world have raised funds for children in need in the places where we all live and work. Often, we don’t get a chance to see the faces of those we help, but today we’re going to introduce you to two young ladies with a remarkable story. Twins Aurelia and Charlene attend FortSchritt, a facility in Aachen, Germany, that offers conductive education to children with movement disorders.</p></div>
The global injectable drug market sees an ever-increasing adoption of high-value biologic drug products. More than half of today’s 20 top selling injectables are biologics, and many of them are delivered in a prefilled syringe. Even though glass syringes are predominantly used for primary containment of parenterals, the (bio)pharmaceutical industry continues to cope with certain limitations associated with glass prefilled systems.
English
Chinese
